Shipment is part of the Company's strategy
to advance its leadership in the global cannabinoid
space
NASDAQ | TSX: ACB
EDMONTON, AB, July 15, 2021 /CNW/ - Aurora Cannabis Inc. (the
"Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian
company defining the future of cannabinoids worldwide, announced
today the delivery of a cannabis shipment worth nearly C$8 million, in one of the largest single
shipments of cannabis that Israel
has received.
The sale is a significant step in advancing the Company's
international medical business, a key strategic priority for Aurora
as a global cannabis company. With leadership in both Canada and Europe, Aurora is uniquely positioned to be a
partner of choice in countries like Israel, where THC recreational markets are
expected to be around the corner, and non-THC cannabinoids, such as
CBD, are advancing toward legalization.
"We are excited about the evolution of the cannabis industry in
Israel and commend the Ministry of
Health and the Israeli Medical Cannabis Agency for ensuring
thoughtful regulation of cannabis, in the best interest of Israeli
cannabis patients," says Miguel
Martin, Chief Executive Officer of Aurora. "We look forward
to continuing to provide high-quality cannabis to Israel, as part of our strategy to expand our
medical cannabis portfolio in key international markets."
The Company, which has a strategic supply agreement with Cantek
Global Ltd., one of Israel's
leaders in the medical cannabis field, intends to supply a minimum
of 4,000 kg of bulk dried flower annually to Israel.
About Aurora
Aurora is a global leader in the cannabis industry serving both
the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis dedicated to helping people improve their lives.
The Company's brand portfolio includes Aurora, Aurora Drift, San
Rafael '71, Daily
Special, AltaVie, MedReleaf, CanniMed, Whistler,
and Reliva CBD. Driven by science and innovation and with
a focus on high-quality cannabis products, Aurora's brands continue
to break through as industry leaders in the medical, performance,
wellness and recreational markets wherever they are launched. For
more information, please visit our website
at www.auroramj.com.
Aurora's common shares trade on the TSX
and NASDAQ under the symbol "ACB" and is a
constituent of the S&P/TSX Composite Index.
Forward Looking Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements made in this news
release include statements regarding the Company's continued
supply of cannabis to Israel and
the amount of cannabis to be supplied to Israel. These forward-looking statements are
only predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release. Forward
looking statements are based on the opinions, estimates and
assumptions of management in light of management's experience and
perception of historical trends, current conditions and expected
developments at the date the statements are made, such as current
and future market conditions, the ability to maintain SG&A
costs in line with current expectations, the ability to achieve
high margin revenues in the Canadian consumer market, the current
and future regulatory environment and future approvals and permits.
Forward-looking statements are subject to a variety of risks,
uncertainties and other factors that management believes to be
relevant and reasonable in the circumstances could cause actual
events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements, including the risks
associated with: entering the U.S. market, the ability to realize
the anticipated benefits associated with the acquisition
of Reliva, achievement of Aurora's business transformation
plan, general business and economic conditions, changes in laws and
regulations, product demand, changes in prices of required
commodities, competition, the effects of and responses to the
COVID-19 pandemic and other risks, uncertainties and factors set
out under the heading "Risk Factors" in the Company's annual
information form dated September 24,
2020 (the "AIF") and filed with Canadian securities
regulators available on the Company's issuer profile on SEDAR
at www.sedar.com and filed with and available on the SEC's
website at www.edgar.gov. The Company cautions that the list
of risks, uncertainties and other factors described in the AIF is
not exhaustive and other factors could also adversely affect its
results. Readers are urged to consider the
risks, uncertainties and assumptions carefully in
evaluating the forward-looking statements and are cautioned not to
place undue reliance on such information. The Company is under no
obligation, and expressly disclaims any intention or obligation, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except
as expressly required by applicable securities law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-delivers-8-million-shipment-of-cannabis-to-israel-301334295.html
SOURCE Aurora Cannabis Inc.